Normocapnia is recommended in intensive care management of patients after out-of-hospital cardiac arrest. While normocapnia is usually achievable, it may be therapeutically challenging, particularly in patients with airflow obstruction. Conventional mechanical ventilation may not be adequate to provide optimal ventilation in such patients. One of the recent advances in critical care management of hypercapnia is the advent of newer, low-flow extracorporeal carbon dioxide clearance devices. These are simpler and less invasive than conventional extracorporeal devices. We report the first case of using a novel, extracorporeal carbon dioxide removal device in Australia on a patient with out-of-hospital cardiac arrest where mechanical ventilation failed to achieve normocapnia.
Patients are usually admitted to the intensive care unit (ICU) after out-of-hospital cardiac arrest (OHCA) if return of spontaneous circulation is achieved after resuscitation. Their mortality remains high despite improvements in pre-hospital management and intensive care post cardiac arrest. Therapeutic hypothermia has improved neurological outcome 1, 2 and the recommendations are to maintain PaCO 2 between 40 and 45 mmHg 3, 4 . While normocapnia is usually achievable, it may be therapeutically challenging, particularly in patients with airflow obstruction or increased physiological dead space.
Conventional mechanical ventilation may not be adequate to provide optimal ventilation in such patients. One of the recent advances in the critical care management of hypercapnia is the advent of newer extracorporeal carbon dioxide clearance devices 5, 6 . These are simpler and less invasive than conventional extracorporeal membrane oxygenation (ECMO) devices. These low blood-flow carbon dioxide clearance devices are effective in the removal of carbon dioxide without contributing significantly to oxygenation.
We report the first use of a novel extracorporeal carbon dioxide removal (ECCO2-R) device in Australia in managing a patient with OHCA where mechanical ventilation failed to achieve normocapnia. The severe hypercapnic acidosis was managed by ECCO2-R using the Hemolung ® Respiratory Assist System (RAS) (ALung Technologies Inc., Pittsburgh, PA, USA).
CASE REPORT

Ethics approval and consent
The Human Research and Ethics Committee of Peninsula Health approved the use of Hemolung ® in our ICU. Approval was also obtained from the Australian Therapeutic Goods Administration (TGA approval number 2013-123) for using Hemolung ® . Consent from the family was obtained to allow reporting of this case.
A 58-year-old male was found unconscious by his wife at 3.00 am. She had last seen him at about 10.00 pm the preceding day. Following instructions provided by the paramedical team, she performed chest compressions until the arrival of the paramedical personnel, who found the patient in pulseless electrical activity. They initiated cardiopulmonary resuscitation as per the Advanced Life Support guidelines and continued this for ten minutes until the return of spontaneous circulation. During resuscitation the patient was intubated and a needle thoracostomy performed for a suspected tension pneumothorax.
The patient had a history of severe chronic obstructive pulmonary disease (COPD), secondary to a more than 40 pack-year history of cigarette smoking, with forced expired volume in one second of 0.41 l (16% of predicted for his age and sex) and diffusing capacity of the lung for carbon monoxide 7.4 ml/min/mmHg (33% of predicted). There was confirmed asbestos exposure in the past but no radiological evidence of parenchymal or pleural disease as a consequence. He was independent with his activities of daily living but with a markedly reduced exercise tolerance, limited to 50 metres on flat ground. He had been admitted to hospital twice in the two weeks preceding this admission with exacerbations of COPD and was awaiting lung transplantation.
On arrival at the emergency department he had decreased breath sounds bilaterally with no evidence of a pneumothorax or new infiltrates on a bedside anterior-posterior chest radiograph. The patient was on a pressure control mode of ventilation with a peak airway pressure target of 35 cmH 2 O, an inspiratory to expiratory time ratio of 1:3.7 and a respiratory rate of 12/minute. He was treated with nebulised salbutamol, ipratropium and high-dose intravenous hydrocortisone, and therapeutic hypothermia 1 was instituted. His endotracheal tube had minimal secretions.
He did not have any evidence of acute intracranial pathology on the plain computed tomography scan of his brain. Computed tomography pulmonary angiogram was not suggestive of pulmonary thromboembolism, pneumothorax or airspace consolidation.
Initial arterial blood gas analysis revealed a PaCO 2 of 82 mmHg and a pH of 7.20. The PaCO 2 was significantly higher than his baseline PaCO 2 of about 50 mmHg when well. He was sedated with morphine and midazolam and paralysed with cisatracurium by infusion to facilitate mechanical ventilation.
Over the next few hours he became increasingly difficult to ventilate, with increased intrinsic positive end-expiratory pressure, decreased alveolar ventilation and an arterial PaCO 2 increasing to 94 mmHg with worsening respiratory acidosis on admission to intensive care. In light of severe hypercapnia and increasing respiratory acidosis not responding to conventional mechanical ventilation, ECCO2-R with Hemolung ® RAS ( Figure 1 ) was initiated to prevent lung injury and secondary brain injury. A detailed description of Hemolung ® has been published previously 7, 8 . Extracorporeal circulation was achieved through a 15.5 French double-lumen catheter (Figure 2) , and the device consisted of a controller and an integrated pump/gas-exchange cartridge. The priming volume of the cartridge is 144 ml and the blood tubing 115 ml (total priming volume of the circuit is 259 ml). The cartridge and circuit are recommended to be used for up to seven days. The cost of using this device in Australia is about A$10,000.
The right internal jugular vein was cannulated under ultrasound guidance. Limited heparinisation was established with intravenous injection of 80 units of heparin per kilogram body weight. Following limited heparinisation (aiming for an activated clotting time of 150 to 180 seconds), extracorporeal carbon dioxide clearance was initiated. Following the introduction of Hemolung ® , it was possible to decrease both the minute ventilation and respiratory rate and optimise the inspiratory to expiratory time ratio to minimise the risk of barotrauma. Excellent clearance of carbon dioxide was achieved through the extracorporeal device.
Over the next three days the improvement in respiratory function facilitated weaning from mechanical ventilation followed by removal of the Hemolung ® (Table 1) . However, the patient remained mechanically ventilated. The average blood-flow during the course of treatment was 454 ml/minute. The carbon dioxide clearance during the first 24, 48 and 72 hours was 87, 66 and 36 ml/minute, respectively. There were no major complications noted while the patient was on Hemolung There was minor oozing from the cannulation site on the first day which resolved by the second day. There was no requirement for transfusion of blood or platelets during the course of treatment.
After liberation from the Hemolung ® , the patient started to show clinical signs of significant hypoxic brain injury, including recurrent generalised myoclonic jerks which were refractory to very high doses of benzodiazepine and propofol infusions, levetiracetam and sodium valproate. His electroencephalogram, obtained three days after the event, revealed suppressed background rhythm and generalised epileptiform discharges. His brainstem reflexes were preserved but a magnetic resonance imaging scan of the brain five days after admission confirmed significant hypoxic ischaemic brain injury. Despite aggressive, multiple anti-epileptic therapies, his myoclonic seizures remained sustained and unresponsive to treatment. By day eight, on the basis of continued myoclonic jerks and significant hypoxic ischaemic brain injury on brain magnetic resonance imaging scan, the neurological prognosis was considered to be extremely poor. The decision to withdraw all life-sustaining therapies and offer palliation was reached after a family meeting. Consistent with the patient's wishes of being an organ donor he progressed to donation after cardiac death and his kidneys were considered suitable for organ donation.
DISCUSSION
In our patient with severe hypercapnic respiratory failure, the use of Hemolung ® was successful and safe in achieving satisfactory carbon dioxide clearance. We used ECCO2-R in our patient, who had an unwitnessed OHCA and end-stage obstructive airway disease as he was on the waiting list for lung transplantation and a short time to return of spontaneous circulation after the initiation of cardiopulmonary resuscitation. Furthermore, the ECCO2-R was minimally invasive. We noted an excellent carbon dioxide clearance soon after initiation of Hemolung ® , with carbon dioxide levels approximating normal values despite the reduction in minute ventilation (Table 1) . Despite its first use in our ICU, no reported complications were observed during the running of the extracorporeal circuit. Our patient was hypothermic during deployment of the device and pleasingly we did not note any untoward haemorrhagic complications.
Despite the novel approach to carbon dioxide clearance, this patient had several poor prognostic features at presentation. These included an unwitnessed arrest, pulseless electrical activity, severe COPD and hypercapnic acidosis, which may have contributed to the poor outcome 4, 9, 10 . Patients with COPD who present to hospital with OHCA are known to have a higher mortality than OHCA patients without COPD. COPD was also found to be an independent predictor of mortality in patients presenting with OHCA 10 . The presence of either hypocapnia or hypercapnia is common after cardiac arrest and is independently associated with poor neurological outcome 4 . While the outcome of this patient was unfavourable, we believe ECCO2-R, and other extracorporeal life assist devices in general, may play a vital role in cardiopulmonary resuscitation and post-resuscitation care in some difficult situations.
This report suggests that the use of less invasive lowflow extracorporeal devices is practical and safe in the setting of a metropolitan ICU. The initiation and use of the Hemolung ® RAS was accomplished by staff with a limited period of education, and the extracorporeal therapy was delivered without complications. The clearance of carbon dioxide was adequate at about 90 ml/minute during the first 24 hours of use, during which time ventilation was difficult. This permitted optimal conditions for prevention of secondary brain, as well as lung, injury. In adult patients with severe respiratory failure the use of an ECMO-based protocol was shown to improve survival without severe disability 11 . However, the use of ECMO and conventional extracorporeal carbon dioxide clearance devices is often limited to a few centres because of the cost associated with its establishment, availability of a multidisciplinary team including cardiac surgeons and perfusionists to maintain the circuit, and the training requirements of the attending medical, nursing and paramedical personnel. In addition to costs and complexities, there are also serious potential complications due to the use of large intravascular catheters, systemic anticoagulation and high blood-flow rates 12 , which can limit the applicability of these conventional extracorporeal devices only to specialised ICUs.
Several low-flow extracorporeal devices have been introduced to clinical practice in the last two decades 8, 13, 14 . These devices appear to be effective in reducing arterial carbon dioxide, less invasive and able to provide partial respiratory support. They may, therefore, have a role in managing patients with severe respiratory failure when mechanical ventilation alone is inadequate. As such, these devices are increasingly used in centres that are not capable of initiating ECMO, and may ultimately prove to be preferable to ECMO in the management of severe hypercapnic respiratory failure not responding to mechanical ventilation. Although these devices may aid in lung ultra-protective mechanical ventilation, further studies are required to define whether these devices can reduce mortality and morbidity of patients with refractory hypercapnic respiratory failure.
CONCLUSION
The low-flow ECCO2-R devices are minimally invasive and may be useful in the management of severe hypercapnic respiratory failure refractory to mechanical ventilation.
